Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehran Jalaie

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Medicinal Chemistry|August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancerJ Jean Cui, Michele McTigue, Mitchell Nambu, et al.
Journal of Medicinal Chemistry|December 5, 2025
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 InhibitorGary M Gallego, Cynthia Palmer, Suvi Orr, et al.
Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Journal of Medicinal Chemistry|March 20, 2023
Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1Rebecca A Gallego, Louise Bernier, Hui Chen, et al.
Journal of Medicinal Chemistry|December 9, 2024
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of CancerRebecca A Gallego, Sujin Cho-Schultz, Matthew Del Bel, et al.
Cancer Cell|March 11, 2025
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safetyCynthia L Palmer, Britton Boras, Bernadette Pascual, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Medicinal Chemistry|August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancerJ Jean Cui, Michele McTigue, Mitchell Nambu, et al.
Journal of Medicinal Chemistry|December 5, 2025
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 InhibitorGary M Gallego, Cynthia Palmer, Suvi Orr, et al.
Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Journal of Medicinal Chemistry|March 20, 2023
Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1Rebecca A Gallego, Louise Bernier, Hui Chen, et al.
Journal of Medicinal Chemistry|December 9, 2024
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of CancerRebecca A Gallego, Sujin Cho-Schultz, Matthew Del Bel, et al.
Cancer Cell|March 11, 2025
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safetyCynthia L Palmer, Britton Boras, Bernadette Pascual, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 3